Patrick Campbell

Announced on July 28, insulin glargine-yfgn (Semglee) becomes the first interchange biosimilar insulin product to receive approval in the FDA's history and is expected to be available by the end of the year.

Despite the notion they are unsafe, a pair of studies demonstrate there were no significant differences in outcomes among heart transplant recipients receiving a donor heart based on a history of illicit drug use or overdose.

A retrospective cohort study with data from nearly 4 million patients with hypertension from the US, Germany, and South Korea found ACEs and ARBs provide similar efficacy for prevention of cardiovascular events, but ACEs were associated with a greater risk of adverse events.

An analysis of a subset of patients from the STAMPEDE trial provides new evidence detailing the quality of life improvements associated with undergoing bariatric surgery in patients with uncontrolled type 2 diabetes.

Practical Cardiology sat down with Javed Butler, MD, following his presentation at ASPC 2021 to discuss how recent advances have impacted prevention of heart failure and how he views the role of primary care/internal medicine in primary prevention.

A cross-sectional analysis of data from the National Center for Health Statistics indicates the presence of 4 cardiovascular risk factors prior to becoming pregnant can help identify pregnancies at increased risk of adverse fetal or maternal outcomes.

A systematic review and meta-analysis of randomized trials suggest use of physical activity trackers, such as pedometers and accelerometers, were linked to increased levels of physical activity versus non-use in patients with cardiometabolic conditions.

Data from a prespecified analysis of DAPA-CKD examining effects of dapagliflozin in patients with stage 4 CKD suggests the impact of the SGLT2 inhibitor in these patients was similar to those seen in the overall trial.

With approval, exenatide extended-release (BYDUREON BCise) becomes the first weekly GLP-1 RA therapy to receive approval for improving glycemic control in pediatric patients aged 10-17 years with type 2 diabetes.

Analysis of more than 40k Medicare beneficiaries suggests increased physical activity, whether it occurs as part of a rehabilitation or not, was associated with decreased risk of all-cause mortality and hospitalizations for heart failure in patients who recently received an implantable cardioverter-defibrillator.

Analysis of data from the UK Biobank cohort suggests consumption of coffee was not linked to an increased risk of arrhythmias, with some evidence indicating habitual use was linked to a decrease in incidence of atrial fibrillation or flutter and supraventricular tachycardia.

A prespecified analysis of patients with stage 4 CKD from DAPA-CKD suggests the magnitude of effects seen with dapagliflozin use among these patients was similar to that seen among patients with normal to moderately impaired kidney function from the trial.

Data from a phase 2 study of women with overweight or obesity and polycystic ovary syndrome suggests use of licogliflozin was associated with significant reductions in hyperinsulinemia and androgenemia in this patient population.

A 412-patient trial comparing 3 dosing regimens of abelacimab versus enoxaparin, results indicate all 3 regimens of abelacimab demonstrated noninferiority against enoxaparin and 2 of the 3 demonstrated superiority against the current standard of care.

With approval announced on July 19, HFX becomes the only spinal cord stimulation therapy approved by the FDA with a specific indication for painful diabetic neuropathy.

The subject of a July 15 meeting, the FDA's Cardiovascular and Renal Drugs Advisory Committee voted 13-1 and 12-2 against recommending approval of roxadustat for treatment of anemia in adult patients with chronic kidney disease not on dialysis and on dialysis, respectively.

A 12-week trial found implementing a dietary approach using a low-fat, vegan diet could help reduce the incidence of moderate-to-severe hot flashes in postmenopausal women.

From 2008 to 2018, the rate of methamphetamine-associated heart failure hospitalizations in California has risen by nearly 600% while the costs associated with these events has risen by more than 800% during that same time frame.

Analysis of more than 35,000 patients with diabetes and depressive disorder indicates patients with greater adherence to antidepressants appeared to experience fewer complications and a lower rate of mortality than those with suboptimal use.

An analysis of data from the Framingham Heart Study Offspring Cohort by investigators at the USDA Human Nutrition Research Center on Aging suggests greater consumption of whole grains was associated with a more preferable cardiometabolic risk profile than lesser consumption or consumption of refined grains.

A study from the Annual Congress of the European Association of Urology suggests undergoing testosterone therapy could improve cardiovascular health and reduce risk of adverse events in men with hypogonadism.

Four of the world's leading cardiology organizations—the ESC, ACC, AHA, and WHF—have collaborated to form a joint opinion statement seeking to address and outline drivers and strategies for mitigation of burnout.

With approval on July 9, finerenone (Kerendia) becomes the first nonsteroidal mineralocorticoid receptor antagonist to receive approval for use in adults with chronic kidney disease associated with type 2 diabetes.

Novartis announced the Complete Response resubmission for inclisiran in a statement on July 6, 2021.

Despite having a favorable vote in a recent FDA AdComm meeting, Provention Bio announced the FDA has issued a CRL for teplizumab for the delay of type 1 diabetes in at-risk individuals.

While many have speculated about the effect of SGLT2 inhibitors in HFpEF for years, EMPEROR-Preserved provides the first evidence from a phase 3 RCT of the safety and efficacy of empagliflozin for use in patients with heart failure across the spectrum of ejection fraction.

A dive into data from the RAND Health and Retirement Study suggests changes in wealth mobility, whether positive or negative, were associated with changes in cardiovascular disease risk.

Data from the SURPASS program presented at ADA 2021 provide insight into the effects of tirzepatide on HbA1c control and body weight in a variety of different patient populations as both an add-on and monotherapy.

While still waiting for regulatory approval, the SCORED and SOLOIST trial have demonstrated the impact of sotagliflozin, a dual SGLT1/2 inhibitor, on patients with type 2 diabetes and chronic kidney disease or heart failure.

Deepak Bhatt, MD, MPH, reflects on the rapid ascent of sotagliflozin (Zynquista) into the spotlight of clinicians specializing in cardiometabolic health thanks to the success of the phase 3 SCORED and SOLOIST trials.